The session will have presentations from 2 different speakers.
Title: Automating Tumor-Specific 3D Cultures For Anticancer Drug Screening
Presenter: Julia Kirshner, Ph.D.
Abstract: Pharmaceutical drug development requires accurate, physiologically-relevant model systems and reproducible, robust assays to evaluate the efficacy and toxicity of investigational agents. Presently, large-scale screening and pre-clinical testing of anti-cancer compounds rely on two-dimensional (2D) cell culture methodologies, where cells are grown flat on a plastic surface lacking critical components of the tissue microenvironment. As such, 2D cultures cannot reliably predict therapeutic potential of the agents under development. 3D culture format solves this problem by supplying both cellular and extracellular components of the tumor microenvironment. However, to date, scaffold-based 3D cultures have not been widely adopted by pharmaceutical industry due to their perceived incompatibility with the high throughput (HTS) format. Here we describe the successful adoption of zPREDICTA’s Reconstructed Lung (r-Lung) 3D culture platform for testing of anti-cancer agents in HTS format using Tecan Freedom EVO® liquid handling platform and D300e Digital Dispenser. We demonstrate high reproducibility and low variability of our non-small cell lung cancer (NSCLC) 3D model set-up for evaluation of anti-NSCLC agents, ultimately providing a physiologically relevant, automated 3D HTS system that can be incorporated throughout the drug development workflow for reliable identification of anti-cancer agents having high probability of therapeutic success.
Title: Using Patient Derived Organoids to Screen Novel and Personalized Drug Combinations in Rare Liver Cancers
Presenter: Ricardo Jose Antonia
Abstract: While there has been a large boom in targeted agents in oncology, these drugs are rarely effective as single agents. Moreover, there is heterogeneity between individuals in their responsiveness to a given therapeutic. Patient derived organoids offer a fast and nimble way to discover novel drug combinations for liver cancers and to study the heterogeneity of response between different individual’s tumors to those drug combinations.